TIA funding allows QEDDI to open to external drug discoveries
TIA is set to boost our capabilities and resources following the announcement of NCRIS 2023 funding by The Hon Jason Clare MP,
TIA-supported facility helps kick-start an Australian-developed cancer drug that has now been approved by the US FDA
Momelotinib, a drug discovered by Australian researchers over several decades, has recently been approved by the US Food and Drug
TIA support bringing a koala vaccine a step closer
Chlamydia is infecting up to half of the koalas living in Queensland and New South Wales, causing blindness and infertility.
New partnership supports advances in therapeutic development research
Research in eye, gum, heart and kidney disease, reproductive and developmental biology, cancer, infections, high blood pressure, therapeutic development, microbiome,
MRFF backs new national venture to strengthen homegrown medicine outcomes
The Commonwealth Government’s Medical Research Future Fund (MRFF) National Critical Research Infrastructure Grant has invested $9.75 million into establishing MedChem
How TIA is helping infectious disease researchers build translational skills
Associate Professor Anthony Kicic leads a team at the Telethon Kids Institute towards a new way of fighting antimicrobial resistance
New biotech company receives funding to halt the progression of kidney disease
TIA has supported kidney disease research that is now underpinning the establishment of new Monash biotech company xCystence Bio. xCystence
Technical feasibility advice part of expanded TIA support schemes
Early-stage research projects in areas such as autoimmune disease, antimicrobial-resistant infections and eye disorders are benefiting from expert advice from
Demand booms for experimental mRNA from UQ BASE
TIA has supported a team from The University of Queensland that is now the biggest supplier of experimental mRNA vaccines
Clamp2 provides vaccine hope for future pandemics
A TIA facility will play an important role in The University of Queensland’s research to take a second-generation molecular clamp
Medical chemist brings commercialisation experience to ATMCF role
Professor Paul Stupple has been appointed the Director of TIA’s Australian Translational Medicinal Chemistry Facility (ATMCF), bringing more than 20
When food kills
Infrastructure and expertise supported by Phenomics Australia and Therapeutic Innovation Australia (TIA) are used in fighting food poisoning toxins. The
Research Infrastructure Specialist Position Paper
The National Research Infrastructure system, embodied as a broad set of Commonwealth investments through NCRIS, is a systemic enabler of
How TIA is helping to accelerate the development of Australian COVID-19 treatments
TIA facilities are contributing to research programs at the Walter and Eliza Hall Institute of Medical Research (WEHI) to develop
TIA supports bid to overcome leading cause of hospital ICU deaths
TIA facilities are core to research into a targeted therapeutic to overcome sepsis, a leading cause of death in hospital
Developing a pain medication that doesn’t cause addiction
People with pain rely heavily on opioid medications, causing side effects and leading to addiction in as many as 18
Virus and superbug vaccines at the core of TIA-supported research
Researchers are building on the University of Queensland’s expertise in vaccine technology and accessing TIA capabilities to develop vaccines suitable
Prescient Therapeutics Limited building LEGO-like solutions to address rapidly mutating cancers
Melbourne-based oncology company Prescient Therapeutics Limited (ASX: PTX) is using TIA facilities to develop a modular cell-based therapy, like LEGO,
